NCT02871817

Brief Summary

The CLEAR study is testing the level of agreement between visual acuity and Amsler grid testing using a mobile vision testing application, Checkup Study, and standard in office methods. In addition the percent of patients able to successfully complete home testing on the digital device will be assessed.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
143

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2016

Geographic Reach
1 country

12 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2016

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

July 18, 2016

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 18, 2016

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

January 26, 2018

Status Verified

January 1, 2018

Enrollment Period

1.7 years

First QC Date

July 18, 2016

Last Update Submit

January 24, 2018

Conditions

Keywords

Near Corrected Visual AcuityEarly Treatment Diabetes Retinopathy StudyAmsler GridHome Monitoring

Outcome Measures

Primary Outcomes (2)

  • Near Corrected Visual Acuity

    Corrected Near Visual Acuity (CNVA) assessed with the Checkup System will be compared to the reference method CNVA (Lebensohn Near Card) in replicated measurements at each of two in-office visits.

    Eight weeks

  • Amsler Grid

    The Amsler Grid assessment with the Checkup will be compared to the reference method Amsler Grid in replicated measurements at each of two in-office visits

    Eight weeks

Secondary Outcomes (2)

  • Feasibility of home testing using Paxos Checkup Mobile application

    Eight weeks

  • Assess repeatability of mobile application testing

    8 weeks

Study Arms (3)

Normal Vision

Patients without significant vision deficit (20/20 vision), when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application

Other: Paxos Checkup Study Mobile Medical Application

Age-related macular degeneration

Patients presenting with dry AMD or neovascular (wet) AMD, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application

Other: Paxos Checkup Study Mobile Medical Application

Diabetic retinopathy

Patients presenting with Diabetic Retinopathy, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application

Other: Paxos Checkup Study Mobile Medical Application

Interventions

The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.

Also known as: Checkup Study
Age-related macular degenerationDiabetic retinopathyNormal Vision

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Study population includes patients with no pathology, patients with Diabetic Retinopathy and patients with Adult Macular Degeneration.

You may qualify if:

  • Male or female 18 years of age and older
  • Best Corrected Near Visual acuity 20/200 or better in study eye(s)
  • Able and willing to make the required study visits
  • Able and willing to provide consent and comply with study assessments for the full duration of the study.
  • Best Corrected Near Visual acuity 20/32 or better in each eye
  • No concurrent systemic illness affecting the retina and vision.
  • Diagnosis of either AMD or DR (all subgroups qualify)

You may not qualify if:

  • Dementia or other neurologic or psychological limitation that would prevent the patient from performing regular self-testing of visual function
  • Other comorbid ocular pathology affecting vision (with the exception of cataract, pseudophakia, refractive error, and/or presbyopia)
  • Inability to successfully undergo training and certify ability to self-test with Paxos Checkup
  • Inability to return for follow up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Mountain View, California, United States

Location

Unknown Facility

Fort Myers, Florida, United States

Location

Unknown Facility

Miami, Florida, United States

Location

Unknown Facility

Tallahassee, Florida, United States

Location

Unknown Facility

Lexington, Kentucky, United States

Location

Unknown Facility

Reno, Nevada, United States

Location

Unknown Facility

Cleveland, Ohio, 44122, United States

Location

Unknown Facility

Nashville, Tennessee, 37215, United States

Location

Unknown Facility

Austin, Texas, United States

Location

Unknown Facility

San Antonio, Texas, United States

Location

Unknown Facility

Spokane, Washington, United States

Location

MeSH Terms

Conditions

Macular DegenerationDiabetic RetinopathyVision Disorders

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Carol Hoang

    Digisight Technologies, Inc.

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 18, 2016

First Posted

August 18, 2016

Study Start

July 1, 2016

Primary Completion

March 1, 2018

Study Completion

March 1, 2018

Last Updated

January 26, 2018

Record last verified: 2018-01

Locations